1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • NCCN Guidelines® Insights: Multiple myeloma, version 3.2022: Featured updates to the NCCN Guidelines
    Guidelines

    Callander, N. S.; Baljevic, M.; Adekola, K.; Anderson, L. D. Jr; Campagnaro, E.; Castillo, J. J.; Costello, C.; Devarakonda, S.; Elsedawy, N.; Faiman, M.; more...
    Journal of the National Comprehensive Cancer Network (2022)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
    Research Letter

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study
    Meeting Abstract

    Trudel, S.; Cohen, A. D.; Krishnan, A. Y.; Fonseca, R.; Spencer, A.; Berdeja, J. G.; Lesokhin, A.; Forsberg, P. A.; Laubach, J. P.; Costa, L. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Prevalence of smoldering multiple myeloma: Results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Thorsteinsdottir, S.; Gislason, G. K.; Aspelund, T.; Rögnvaldsson, S.; Oskarsson, J. T. T.; Petirsdottir, I.; Sigurdsson, J. K.; Sigurdardottir, G. A.; Thordardottir, A. R.; Vidarsson, B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Estimating selection bias in previous monoclonal gammopathy of undetermined significance research - the importance of screening: Results from the population-based screening study Iceland screens, treats or prevents multiple myeloma (iStopMM)
    Meeting Abstract

    Sigurbergsdóttir, A. Ý.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study
    Meeting Abstract

    Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1
    Meeting Abstract

    Sebag, M.; Raje, N. S.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Monoclonal gammopathy of undetermined significance and COVID-19: Results from the population-based Iceland screens treats or prevents multiple myeloma study (iStopMM)
    Meeting Abstract

    Rögnvaldsson, S; Eythorsson, E.; Thorsteinsdottir, S.; Vidarsson, B.; Onudarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Horsteinsdottir, I.; Olafsson, I.; Runolfsdottir, H. L.; more...
    Blood (2021)

    Fulltext@MSK | Save